Faron Pharmaceuticals Oy
Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress
Bexmarilimab mode of action in AML/MDS supported with durable Clever-1. | June 9, 2023
Faron Pharmaceuticals Oy (LON:FARN – Get Rating) shares passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 310.88 ($3.89) and traded as low as GBX 292 ($3.66). Faron Pharmaceuticals Oy shares last traded at GBX 292 ($3.66), with a volume of 7,156 shares trading […]
FINLAND - Faron Pharmaceuticals Oy , a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the release of further insights from its Phase. | April 25, 2023
Faron Pharmaceuticals Oy (LON:FARN – Get Rating)’s share price rose 1.9% during trading on Monday . The stock traded as high as GBX 320 ($3.96) and last traded at GBX 317 ($3.92). Approximately 22,760 shares changed hands during mid-day trading, an increase of 135% from the average daily volume of 9,673 shares. The stock had […]